{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:42:06Z","timestamp":1790487726247,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19bm0804003h0003"],"award-info":[{"award-number":["19bm0804003h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP 18ek0109329h0001"],"award-info":[{"award-number":["JP 18ek0109329h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.reth.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T06:12:52Z","timestamp":1564121572000},"page":"143-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis \u2013 Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I\/IIa clinical trial (ROPALS trial)"],"prefix":"10.1016","volume":"11","author":[{"given":"Satoru","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komei","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Saya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2019.07.002_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2019.07.002_bib2","first-page":"494","article-title":"Prevalence and incidence of amyotrophic lateral sclerosis in Japan","volume":"24","author":"Doi","year":"2014","journal-title":"J\u00a0Epidemiol"},{"key":"10.1016\/j.reth.2019.07.002_bib3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A\u00a0controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2019.07.002_bib4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Doseranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"issue":"6 Suppl 4","key":"10.1016\/j.reth.2019.07.002_bib5","first-page":"S242","article-title":"A\u00a0confirmatory dose-ranging study of riluzole in ALS. ALS\/Riluzole Study Group-II","volume":"47","author":"Lacomblez","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.reth.2019.07.002_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0022-510X(00)00426-3","article-title":"German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)","volume":"180","author":"Pongratz","year":"2000","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.reth.2019.07.002_bib7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archneur.55.4.526","article-title":"An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole","volume":"55","author":"Riviere","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.reth.2019.07.002_bib8","first-page":"851","article-title":"Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan","volume":"182","author":"Yanagisawa","year":"1997","journal-title":"Igakuno Ayumi"},{"key":"10.1016\/j.reth.2019.07.002_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/17482960600881870","article-title":"Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)","volume":"7","author":"Yoshino","year":"2006","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.reth.2019.07.002_bib10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.reth.2019.07.002_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(99)01688-1","article-title":"Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist","volume":"838","author":"Iida","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.reth.2019.07.002_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1007672414239","article-title":"Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist","volume":"26","author":"Tanaka","year":"2001","journal-title":"Neurochem Res"},{"key":"10.1016\/j.reth.2019.07.002_bib13","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/j.1460-9568.2005.04438.x","article-title":"Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons","volume":"22","author":"Du","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.reth.2019.07.002_bib14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nn1265","article-title":"Dopamine depletion impairs precursor cell proliferation in Parkinson disease","volume":"7","author":"H\u00f6glinger","year":"2004","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.reth.2019.07.002_bib15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1177\/0091270010379412","article-title":"Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects","volume":"51","author":"Bozik","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.reth.2019.07.002_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/17482960701791234","article-title":"R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS","volume":"9","author":"Wang","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.reth.2019.07.002_bib17","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/nm.2579","article-title":"The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis","volume":"17","author":"Cudkowicz","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2019.07.002_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.reth.2019.07.002_bib19","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.037424","article-title":"Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis","volume":"12","author":"De Giorgio","year":"2019","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.reth.2019.07.002_bib20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/s41591-018-0140-5","article-title":"Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent","volume":"24","author":"Fujimori","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2019.07.002_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.reth.2019.07.002_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/21678421.2012.762930","article-title":"The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials","volume":"14","author":"Berry","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.reth.2019.07.002_bib23","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.reth.2019.07.002_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/geront\/20.6.649","article-title":"Relatives of the impaired elderly: correlates of feelings of burden","volume":"20","author":"Zarit","year":"1980","journal-title":"Gerontol"},{"key":"10.1016\/j.reth.2019.07.002_bib25","series-title":"The memory and behaviour problems checklist 1987R and the burden Interview","author":"Zarit","year":"1990"},{"key":"10.1016\/j.reth.2019.07.002_bib26","unstructured":"Mitsubishi Tanabe Pharma Co., Ltd: second confirmatory test (in-house material)."},{"key":"10.1016\/j.reth.2019.07.002_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-510X(00)00420-2","article-title":"The amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-40): tests of data quality, score reliability and response rate in a survey of patients","volume":"180","author":"Jenkinson","year":"2000","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.reth.2019.07.002_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/146608299300080022","article-title":"Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40","volume":"1","author":"Jenkinson","year":"1999","journal-title":"Amyotrophic Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.reth.2019.07.002_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.0000000000002941","article-title":"Quantitative strength testing in ALS clinical trials","volume":"87","author":"Shefner","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.reth.2019.07.002_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1212\/WNL.24.8.721","article-title":"The administration of guanidine in amyotrophic lateral sclerosis","volume":"24","author":"Norris","year":"1974","journal-title":"Neurology"},{"key":"10.1016\/j.reth.2019.07.002_bib31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s00455-017-9797-z","article-title":"Maximum tongue pressure is associated with swallowing dysfunction in ALS patients","volume":"32","author":"Hiraoka","year":"2017","journal-title":"Dysphagia"},{"key":"10.1016\/j.reth.2019.07.002_bib32","first-page":"8343705","article-title":"Verification of a motion sensor for evaluating physical activity in COPD patients","volume":"2018","author":"Miyamoto","year":"2018","journal-title":"Can Respir J"},{"issue":"suppl","key":"10.1016\/j.reth.2019.07.002_bib33","first-page":"22","article-title":"Intrinsic and extrinsic psychosis in Parkinson's disease","volume":"248","author":"Wolters","year":"2001","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.reth.2019.07.002_bib34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2125.1989.tb03524.x","article-title":"A\u00a0dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist","volume":"28","author":"Acton","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reth.2019.07.002_bib35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"Kaye","year":"2000","journal-title":"Clin Pharmacokinet"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320419300458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320419300458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:39:08Z","timestamp":1762450748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320419300458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"alternative-id":["S2352320419300458"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2019.07.002","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.207\/v1","asserted-by":"object"}]},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis \u2013 Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I\/IIa clinical trial (ROPALS trial)","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}